MAI Capital Management’s Iterum Therapeutics ITRM Stock Holding History

MAI Capital Management’s Portfolio ITRM Stock Details ITRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-35,000	Closed	-$1.05K	–	3405
2026 Q1	$1.05K	Buy	+35,000	New	+$8.78K	﹤0.01%	4161

Other funds holding ITRM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

CCMW

Cypress Capital Management (Wyoming) Sheridan, Wyoming $120M AUM 63.01% 1-Year Est. Return

MAI Capital Management's ITRM Position: Q2 2026 in Review

MAI Capital Management sold out of Iterum Therapeutics (ITRM) in Q2 2026, closing a stake of 35,000 shares — an estimated $1.05K sold.

MAI Capital Management first reported a position in ITRM in Q1 2026 and held it in 1 quarter. The position peaked at $1.05K in Q1 2026. 2 funds tracked by Wall St. Rank hold ITRM as of Q2 2026.

MAI Capital Management reported no remaining Iterum Therapeutics position as of Q2 2026 after selling out during the quarter.
MAI Capital Management sold 35,000 Iterum Therapeutics shares in Q2 2026, an estimated $1.05K.
MAI Capital Management first reported a position in Iterum Therapeutics in Q1 2026 and held it in 1 quarter.
MAI Capital Management's Iterum Therapeutics position peaked at $1.05K in Q1 2026.
2 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.